Reported 9 months ago
The US House Ways and Means Committee is set to vote on a proposal allowing Medicare to cover GLP-1 weight-loss drugs like Novo Nordisk's Wegovy and Eli Lily's Zepbound. The bill aims to amend part of the Treat and Reduce Obesity Act of 2023 by providing continued coverage under Medicare for seniors who have been on obesity drugs for at least one year before enrolling in Medicare, excluding those overweight with related diseases. The vote scheduled for tomorrow marks a significant milestone for the long-waited bill, with both companies lobbying for its passage. The congressional budget office will estimate Medicare's cost implications if the bill is approved.
Source: YAHOO